Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Alpelisib

February 2026

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Alpelisib

Dosage Form: Granules

Route: Oral

Strength: 50 mg/packet

Recommended Study: One in vivo bioequivalence study with pharmacokinetic endpoints

1. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 50 mg/packet at the administered dose of 50 mg
   Subjects: Healthy males and non-pregnant, non-lactating females
   Additional comments:
   - Exclude subjects with risk factors for prolonged QTc interval and Torsades de Pointes. Exclude subjects with a history of drug hypersensitivity to prevent severe cutaneous adverse reactions. Females of reproductive potential should use effective contraception during the study and for one week after the last dose. Males with female partners of reproductive potential should use condoms and effective contraception during the study and one week after the last dose.
   - Follow the direct oral administration instructions described in the reference listed drug (RLD) labeling.

Analyte to measure: Alpelisib in plasma

Bioequivalence based on (90% CI): Alpelisib

Waiver request of in vivo testing of additional strength: Not applicable

Dissolution test method and sampling times: Dissolution test(s) should be included for quality control. Provide a dissolution method development report for the test product containing information and data that demonstrate appropriateness of the selected dissolution method and sampling times, such as the discriminating ability to detect changes in critical quality attributes that could potentially impact drug product performance.

In vitro feeding tube studies: The RLD labeling states that the product can be administered by a nasogastric (NG) or gastrostomy (G) tube after preparation. Refer to the most recent version of the guidance for industry *Oral Drug Products Administered Via Enteral Feeding Tube: In Vitro Testing and Labeling Recommendations*[a] for conducting the in vitro feeding tube studies including comparative recovery testing, sedimentation volume and redispersibility testing, in-use stability testing, and particle size distribution study.

Testing tube: NG tube (5 French) and G tube (12 French)

1. Comparative recovery testing
    - Three different configurations of 5 French NG tubes, defined by materials (e.g., polyvinylchloride, silicone, polyurethane) and/or designs (e.g., number of ports/eyes, open or closed distal end), including:
        i. One configuration made of polyurethane
        ii. One configuration made of silicone
        iii. One additional configuration
    - Three different configurations of 12 French G tubes, including:
        i. One configuration made of silicone
        ii. Two additional configurations
        iii. At least one tube should be tested with an inflated balloon design
    - Reporting of the pH value of the water
    - Holding times of 0 and 60 minutes
2. Sedimentation volume and redispersibility testing
3. In-use stability testing
4. Particle size distribution study

Document History: Recommended February 2026

Unique Agency Identifier: PSG_218466

[a] For the most recent version of a guidance, refer to the FDA guidance website at https://www.fda.gov/regulatory-information/search-fda-guidance-documents.